Biotechnology, RNA interference, Adeno-associated virus, RNA, Organism, Gene
Feng Zhang’s quiet spinout snares $215M in a race for the next big CRISPR company
After Sigilon Therapeutics’ $126 million IPO last December, COO Devyn Smith started getting calls. Job offers, mostly, for this biotech or that, none that quite hit. Then a recruiter reached out about an opening at a spinout from Feng Zhang’s MIT CRISPR lab that, despite a flashy launch, ...
Feng Zhang’s quiet spinout snares $215M in a race for the next big CRISPR company
After Sigilon Therapeutics’ $126 million IPO last December, COO Devyn Smith started getting calls. Job offers, mostly, for this biotech or that, none that quite hit. Then a recruiter ...
We are sorry, we could not find the related article
If you are curious about Biotech Essentials and Career and Jobs
Please click on:
Subscribe to Biotech Essentials - Career and Jobs
Feng Zhang's lab develops potential breakthrough in RNA editing delivery using 'ultracompact' versions of Cas13
As one of the pioneers behind CRISPR, the Broad Institute's Feng Zhang has fashioned himself into a gene editing Renaissance man in recent years with a finger in every pie. For RNA editing, ...
New CRISPR Startups Get a Leg Up
Pioneering CRISPR researchers have been on each other’s heels since they began developing their gene editing tools. Now they may be spreading out as they guide new startups along divergent ...
GenEdit strikes Eli Lilly gold with $26M for gene therapy delivery system designed to fight side effects
GenEdit, developed out of the lab of UC-Berkeley, hopes to deliver gene therapies without the toxic side effects that have hampered current delivery systems. Now, it has $26 million in ...
CRISPR start-ups turn attention toward delivery
Feldan Therapeutics, GenEdit, and Hunterian Medicine are tinkering with molecular packaging to help get the gene-editing system into the body
Making CRISPR safer with new enzyme-based prediction tool
A new technique will help scientists choose the best available gene editing option for any given indication, making CRISPR technology safer, cheaper, and more effective. The tool is ...
Senior Scientist Molecular Virology
Why Patients Need You Pfizer's purpose is to deliver breakthroughs that change patients' lives. Research and Development is at the heart of fulfill...
CRISPR-Cas9: The Gene Editing Tool Changing the World
CRISPR-Cas9 has taken the world by storm with the promise of making gene editing much easier and faster than ever before. But how does CRISPR actually work? How can biology research benefit ...
California Passed the Country’s First Law to Prevent Genetic Biohacking
The topic is largely taboo among scientists, and there’s widespread agreement that non-medical applications of the technology should be out of bounds.
CRISPR, with new partner, to develop gene editing therapies for ALS, nerve disorder
A deal with biotech startup Capsida, which recently raised $140 million, gives CRISPR access to a Caltech technology that aims to improve the delivery of genetic medicines.
A simple guide to CRISPR, one of the biggest science stories of the decade
It could revolutionize everything from medicine to agriculture. Better read up now.
Out of prison, the ‘father of gene therapy’ faces a harsh reality: a tarnished legacy and an ankle monitor
In an exclusive interview, disgraced gene therapy pioneer Dr. W. French Anderson reflects on the science he missed while imprisoned for sexual molestation.
Moderna's CEO spells out its new M&A strategy, including what the $160 billion biotech is looking for in gene editing
Moderna likely won't acquire a gene-editing company, CEO Stephane Bancel said, but would like to license in specific editing technologies.
Gene editing is back in the spotlight
A better way to edit DNA and a Russian scientist announces plans to make more designer babies
Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol Levels in Nonhuman Primates
Study Led by Gene Therapy Program at the University of Pennsylvania Published in Molecular Therapy
ATUM Announces Issuance of US Patents Covering Novel Enzymes Critical to Genome Engineering Applications
New patents cover three novel transposons that enable the efficient and broad genome engineering of mammalian cells using the company’s Leap-In Transposase® platform August 11, 2021 08:00 ...